Zicronapine (/zaɪˈkrɒnəpiːn/ zye-KRON-ə-peen, previously known as Lu 31-130) is an atypical antipsychotic medication[1] formerly under development by H. Lundbeck A/S. In phase II studies zicronapine showed statistically significant separation from placebo and convincing efficacy and safety data when compared to olanzapine.[2]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C22H27ClN2 |
Molar mass | 354.92 g·mol−1 |
3D model (JSmol) |
|
| |
|
Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.[3]
In 2014 Lundbeck removed zicronapine from its development portfolio in favor of pursuing the more promising antipsychotic Lu AF35700 (a prodrug of Lu AF356152).[4]